Prostate cancer Companies | Market Research Future

Top Industry Leaders in the Prostate cancer Market

*Disclaimer: List of key companies in no particular orderLatest Prostate cancer diagnosis and therapy Companies Update

Oct 2023: According to Astellas Pharma Inc., the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on October 12 regarding the use of VEOZA™ (fezolinetant) 45 mg every day for the treatment of mild to severe vasomotor symptoms (VMS) related to menopause.4. Hot flashes or night sweats, commonly referred to as VMS, are typical menopausal symptoms.5,6 Fezolinetant will be a first-in-class, nonhormonal therapeutic option to lessen moderate to severe vasomotor symptoms (VMS) associated with menopause if authorized by the European Commission (EC). To lessen the incidence and severity of hot flashes and night sweats, fezolinetant prevents neurokinin B (NKB) from binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron. This helps to restore equilibrium in the hypothalamus, the brain's temperature control center.

Aug 2023: According to statements from investor Artisan Partners, Bayer must undergo significant changes, including the "de-merging" of two of its three core business units. According to the report, this request for modification is one more in a long line of requests for change from different investors. Bluebell Capital Partners, an activist shareholder, had also called for the company's dissolution earlier this year. Moreover, well-known investors like the mutual fund group Deka had harsh criticism for the company's past management. Some investors have proposed that dividing the healthcare and agriculture sectors into two distinct companies would be an easy fix. According to Artisan, the drug-to-pesticide company should look for new owners for its pharmaceutical and over-the-counter businesses.

List of Prostate cancer diagnosis and therapy Key companies in the market